FTD Subtype Comparison Matrix — bvFTD vs svPPA vs nfPPA vs logopenic

FTD Subtype Comparison Matrix

Frontotemporal Dementia (FTD) encompasses a spectrum of clinically and pathologically heterogeneous disorders. This comparison matrix provides a detailed analysis of the four primary FTD subtypes: behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), nonfluent/agrammatic variant PPA (nfvPPA), and logopenic variant primary progressive aphasia (lvPPA).

> See Also: [Frontotemporal Dementia Overview](/diseases/frontotemporal-dementia), [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy), [GRN Gene](/genes/grn), [MAPT Gene](/genes/mapT), [C9orf72 Gene](/genes/c9orf72)

Overview Comparison

| Feature | bvFTD | svPPA | nfvPPA | lvPPA |
|---------|-------|-------|--------|-------|
| Core Syndrome | Behavioral variant | Language variant | Language variant | Language variant |
| Primary Deficit | Behavior/social cognition | Word meaning/object knowledge | Speech production | Word retrieval/repetition |
| Typical Age of Onset | 45-65 years | 50-70 years | 50-70 years | 60-75 years |
| Disease Duration | 6-12 years | 8-15 years | 6-12 years | 6-10 years |
| Prevalence (of FTD) | ~60% | ~20% | ~15% | ~5% |

Clinical Features

Behavioral Variant FTD (bvFTD)

Core Diagnostic Features (Rascovsky criteria):

FTD Subtype Comparison Matrix

Frontotemporal Dementia (FTD) encompasses a spectrum of clinically and pathologically heterogeneous disorders. This comparison matrix provides a detailed analysis of the four primary FTD subtypes: behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), nonfluent/agrammatic variant PPA (nfvPPA), and logopenic variant primary progressive aphasia (lvPPA).

> See Also: [Frontotemporal Dementia Overview](/diseases/frontotemporal-dementia), [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy), [GRN Gene](/genes/grn), [MAPT Gene](/genes/mapT), [C9orf72 Gene](/genes/c9orf72)

Overview Comparison

| Feature | bvFTD | svPPA | nfvPPA | lvPPA |
|---------|-------|-------|--------|-------|
| Core Syndrome | Behavioral variant | Language variant | Language variant | Language variant |
| Primary Deficit | Behavior/social cognition | Word meaning/object knowledge | Speech production | Word retrieval/repetition |
| Typical Age of Onset | 45-65 years | 50-70 years | 50-70 years | 60-75 years |
| Disease Duration | 6-12 years | 8-15 years | 6-12 years | 6-10 years |
| Prevalence (of FTD) | ~60% | ~20% | ~15% | ~5% |

Clinical Features

Behavioral Variant FTD (bvFTD)

Core Diagnostic Features (Rascovsky criteria):

Supporting Features:

• Executive dysfunction (planning, organization, mental flexibility)
• Social cognition deficits (recognizing emotions, social cues)
• Motor behaviors (fidgeting, pacing, wandering)
• Dietary changes (binge eating, food preferences)
• Loss of insight (unawareness of changes)

Semantic Variant PPA (svPPA)

Core Features:

• Anomia — Word-finding difficulty, particularly for low-frequency items
• Single-word Comprehension Deficit — Loss of word meaning, especially for objects
• Surface Dyslexia — Reading words with irregular pronunciation
• Object Agnosia — Inability to recognize objects despite intact vision
• Preserved Speech Fluency — Fluent, grammatically correct speech with empty content
• Preserved Repetition — Normal repetition ability

• Loss of knowledge about people and objects
• Behavioral features similar to bvFTD in later stages
• Rigid food preferences (sweet foods)

Nonfluent/Agrammatic Variant PPA (nfvPPA)

Core Features:

• Agrammatism — Omission of function words, simplified grammar, short phrases
• Hesitant/Slow Speech — Effortful, halting speech production
• Phonological Errors — Sound substitutions, omissions, distortions
• Motor Speech Impairment — Apraxia of speech
• Preserved Word Comprehension — Understanding of single words relatively intact
• Preserved Object Knowledge — Object recognition maintained

• Reading/writing impairment (spelling errors)
• Impaired sentence comprehension for complex sentences
• Aprosodia (monotone speech)
• Mildbehavioral changes possible

Logopenic Variant PPA (lvPPA)

Core Features:

• Word-finding Pauses — Frequent pauses during speech to retrieve words
• Phonological Errors — Sound-level errors (substitutions, transpositions)
• Impaired Repetition — Particularly for sentences, phrases
• Spared Comprehension — Single-word and sentence comprehension intact
• Spared Speech Fluency — Generally fluent, not halting like nfvPPA
• Preserved Grammar — Grammatical structure preserved

Imaging Patterns

Structural MRI (Typical Patterns)

| Subtype | Key Findings | Regions Affected |
|---------|-------------|------------------|
| bvFTD | Symmetric or asymmetric frontal/temporal atrophy | Orbitofrontal, dorsolateral prefrontal, anterior temporal |
| svPPA | Left anterior temporal lobe atrophy (often asymmetric) | Left anterior temporal pole, inferior temporal |
| nfvPPA | Left posterior frontal/inferior parietal atrophy | Left inferior frontal gyrus, premotor, insular |
| lvPPA | Left posterior temporal/parietal atrophy | Left temporoparietal junction, superior temporal |

FDG-PET Patterns

| Subtype | Hypometabolism Pattern |
|---------|----------------------|
| bvFTD | Frontal and anterior temporal lobes, anterior cingulate |
| svPPA | Left anterior temporal and inferior frontal |
| nfvPPA | Left inferior frontal and premotor |
| lvPPA | Left posterior temporal and parietal |

Tau PET (Flortaucipir)

• bvFTD: Variable uptake — positive in tauopathy (CBD, PSP), negative in TDP-43 cases
• svPPA: Typically negative (TDP-43 pathology)
• nfvPPA: May show uptake in some cases (tauopathy)
• lvPPA: Often positive (underlying AD pathology in majority of cases)

Genetic Associations

Known Genetic Causes

| Gene | Protein | Inheritance | Subtype Association | Pathology |
|------|---------|-------------|---------------------|-----------|
| MAPT | Tau protein | Autosomal dominant | bvFTD, PSP | FTLD-tau (3R/4R tau) |
| GRN | Progranulin | Autosomal dominant | bvFTD, CBD, PNFA | FTLD-TDP type A |
| C9orf72 | Dipeptide repeats | Autosomal dominant | bvFTD, ALS-FTD | FTLD-TDP type B |
| VCP | Valosin-containing protein | Autosomal dominant | bvFTD, IBM | FTLD-TDP type IV |
| FUS | Fused in sarcoma | Autosomal dominant | bvFTD | FTLD-FUS |
| CHCHD10 | Coiled-coil-helix-coiled-coil-helix domain 10 | Autosomal dominant | bvFTD, ALS-FTD | FTLD-TDP |

Frequency by Subtype

| Subtype | Familial % | Most Common Genes |
|---------|------------|-------------------|
| bvFTD | 30-40% | MAPT, GRN, C9orf72 |
| svPPA | 20-30% | GRN, MAPT |
| nfvPPA | 30-40% | GRN, MAPT |
| lvPPA | ~10% | Usually sporadic (APP/PSEN mutations rare) |

Pathological Classification

FTLD Subtypes

| Clinical Syndrome | Most Common Pathology | Other Possible Pathologies |
|-----------------|----------------------|---------------------------|
| bvFTD | FTLD-TDP (45%), FTLD-tau (40%) | FTLD-FUS (10%) |
| svPPA | FTLD-TDP type C (90%) | FTLD-tau, AD |
| nfvPPA | FTLD-tau type A (70%) | FTLD-TDP, AD |
| lvPPA | AD pathology (70-80%) | FTLD-TDP, FTLD-tau |

TDP-43 Subtypes

| FTLD-TDP Type | Clinical Correlates |
|--------------|--------------------|
| Type A (neuronal intranuclear inclusions) | bvFTD, nfvPPA, CBD |
| Type B (neuronal cytoplasmic inclusions) | bvFTD, ALS-FTD |
| Type C (DNR — dystrophic neurites) | svPPA |
| Type IV (VIP) | VCP-mutation FTD |

Treatment Approaches

Current Symptomatic Management

| Approach | bvFTD | svPPA | nfvPPA | lvPPA |
|----------|-------|-------|--------|-------|
| SSRIs | First-line for disinhibition, compulsions | Limited benefit | Limited benefit | Not effective |
| Antipsychotics | For severe agitation (off-label) | Not recommended | Not recommended | Not recommended |
| Stimulants | For apathy (low-dose) | Not used | Not used | Not used |
| Speech Therapy | Limited | Communication strategies | Speech production | Word retrieval strategies |
| Occupational Therapy | Safety assessment, routines | Adaptation strategies | Adaptation strategies | Adaptation strategies |

Disease-Modifying Therapies in Development

| Target | Approach | Development Stage | Relevance |
|--------|----------|------------------|-----------|
| Progranulin | GRN gene therapy, progranulin infusion | Preclinical/Phase 1 | GRN carriers (all subtypes) |
| C9orf72 | ASOs, gene silencing | Preclinical | C9orf72 carriers |
| Tau | Anti-tau antibodies, ASOs | Phase 2/3 | MAPT carriers, tauopathy cases |
| TDP-43 | ASOs targeting TDP-43 | Preclinical | TDP-43 pathology cases |

Non-Pharmacological Interventions

| Intervention | Application |
|-------------|-------------|
| Behavioral strategies | Structured routines, environmental modifications for bvFTD |
| Communication therapy | Augmentative/alternative communication for language variants |
| Caregiver education | Understanding subtype-specific needs, safety planning |
| Swallow assessment | Progressive dysarthria can affect swallowing safety |

Differential Diagnosis

FTD vs Alzheimer's Disease

| Feature | FTD | AD |
|---------|-----|---|
| Onset age | Earlier (45-65) | Later (65+) |
| Memory | Preserved early | Impaired early |
| Visuospatial | Preserved early | Impaired early |
| Language | Primary in variants | Secondary, late |
| Behavior | Early, prominent | Late, mild |
| MRI | Frontal/temporal atrophy | Posterior atrophy (hippocampus) |
| FDG-PET | Frontal/temporal hypometabolism | Posterior cingulate, temporoparietal |

Among FTD Subtypes

| Feature | svPPA vs nfvPPA | bvFTD vs svPPA |
|---------|-----------------|----------------|
| Speech fluency | svPPA: fluent; nfvPPA: nonfluent | svPPA: fluent; bvFTD: variable |
| Comprehension | svPPA: impaired for words; nfvPPA: preserved | svPPA: impaired for objects |
| Behavior | nfvPPA: late/rare; svPPA: late | svPPA: late; bvFTD: early |
| MRI | Different atrophy patterns | svPPA: left temporal; bvFTD: frontal |

Prognostic Factors

Positive Prognostic Factors

• Later age of onset
• Slower progression on neuropsychological measures
• Preserved activities of daily living
• Intact socioemotional responsiveness

Negative Prognostic Factors

• Earlier age of onset (particularly <50 years)
• Rapid progression (particularly with motor features)
• GRN mutations (more rapid progression than MAPT)
• Comorbid neuropsychiatric symptoms

Survival

| Subtype | Median Survival from Onset |
|---------|---------------------------|
| bvFTD | 7-10 years |
| svPPA | 10-15 years |
| nfvPPA | 6-12 years |
| lvPPA | 6-10 years |

Research Directions

Biomarker Development

• Blood-based biomarkers: Neurofilament light chain (NfL) for progression monitoring
• CSF biomarkers: Total tau, p-tau181, beta-amyloid for differential diagnosis
• Genetic testing: Increasingly important for counseling and clinical trials

Clinical Trial Eligibility

| Factor | Considerations |
|--------|---------------|
| Stage | Early stage most appropriate for disease-modifying trials |
| Genotype | GRN, MAPT, C9orf72 carriers may have specific trial eligibility |
| Pathology | Tau PET status informs eligibility for anti-tau trials |
| Comorbidities | Exclude significant vascular disease, psychiatric illness |

References